Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152162065> ?p ?o ?g. }
- W2152162065 endingPage "1122" @default.
- W2152162065 startingPage "1111" @default.
- W2152162065 abstract "Follicular lymphoma is a clinically and genetically heterogeneous disease, but the prognostic value of somatic mutations has not been systematically assessed. We aimed to improve risk stratification of patients receiving first-line immunochemotherapy by integrating gene mutations into a prognostic model.We did DNA deep sequencing to retrospectively analyse the mutation status of 74 genes in 151 follicular lymphoma biopsy specimens that were obtained from patients within 1 year before beginning immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These patients were recruited between May 4, 2000, and Oct 20, 2010, as part of a phase 3 trial (GLSG2000). Eligible patients had symptomatic, advanced stage follicular lymphoma and were previously untreated. The primary endpoints were failure-free survival (defined as less than a partial remission at the end of induction, relapse, progression, or death) and overall survival calculated from date of treatment initiation. Median follow-up was 7·7 years (IQR 5·5-9·3). Mutations and clinical factors were incorporated into a risk model for failure-free survival using multivariable L1-penalised Cox regression. We validated the risk model in an independent population-based cohort of 107 patients with symptomatic follicular lymphoma considered ineligible for curative irradiation. Pretreatment biopsies were taken between Feb 24, 2004, and Nov 24, 2009, within 1 year before beginning first-line immunochemotherapy consisting of rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP). Median follow-up was 6·7 years (IQR 5·7-7·6).We established a clinicogenetic risk model (termed m7-FLIPI) that included the mutation status of seven genes (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11), the Follicular Lymphoma International Prognostic Index (FLIPI), and Eastern Cooperative Oncology Group (ECOG) performance status. In the training cohort, m7-FLIPI defined a high-risk group (28%, 43/151) with 5-year failure-free survival of 38·29% (95% CI 25·31-57·95) versus 77·21% (95% CI 69·21-86·14) for the low-risk group (hazard ratio [HR] 4·14, 95% CI 2·47-6·93; p<0·0001; bootstrap-corrected HR 2·02), and outperformed a prognostic model of only gene mutations (HR 3·76, 95% CI 2·10-6·74; p<0·0001; bootstrap-corrected HR 1·57). The positive predictive value and negative predictive value for 5-year failure-free survival were 64% and 78%, respectively, with a C-index of 0·80 (95% CI 0·71-0·89). In the validation cohort, m7-FLIPI again defined a high-risk group (22%, 24/107) with 5-year failure-free survival of 25·00% (95% CI 12·50-49·99) versus 68·24% (58·84-79·15) in the low-risk group (HR 3·58, 95% CI 2·00-6·42; p<0.0001). The positive predictive value for 5-year failure-free survival was 72% and 68% for negative predictive value, with a C-index of 0·79 (95% CI 0·69-0·89). In the validation cohort, risk stratification by m7-FLIPI outperformed FLIPI alone (HR 2·18, 95% CI 1·21-3·92), and FLIPI combined with ECOG performance status (HR 2·03, 95% CI 1·12-3·67).Integration of the mutational status of seven genes with clinical risk factors improves prognostication for patients with follicular lymphoma receiving first-line immunochemotherapy and is a promising approach to identify the subset at highest risk of treatment failure.Deutsche Krebshilfe, Terry Fox Research Institute." @default.
- W2152162065 created "2016-06-24" @default.
- W2152162065 creator A5000874374 @default.
- W2152162065 creator A5002179064 @default.
- W2152162065 creator A5003947352 @default.
- W2152162065 creator A5004172458 @default.
- W2152162065 creator A5004552630 @default.
- W2152162065 creator A5012101254 @default.
- W2152162065 creator A5015242520 @default.
- W2152162065 creator A5021170936 @default.
- W2152162065 creator A5022190254 @default.
- W2152162065 creator A5022657765 @default.
- W2152162065 creator A5022658681 @default.
- W2152162065 creator A5026641386 @default.
- W2152162065 creator A5026688095 @default.
- W2152162065 creator A5028397596 @default.
- W2152162065 creator A5028664304 @default.
- W2152162065 creator A5031758990 @default.
- W2152162065 creator A5033079310 @default.
- W2152162065 creator A5033935778 @default.
- W2152162065 creator A5035277761 @default.
- W2152162065 creator A5039924049 @default.
- W2152162065 creator A5042300762 @default.
- W2152162065 creator A5043505357 @default.
- W2152162065 creator A5046049357 @default.
- W2152162065 creator A5048714300 @default.
- W2152162065 creator A5057290942 @default.
- W2152162065 creator A5061361157 @default.
- W2152162065 creator A5064075585 @default.
- W2152162065 creator A5064311858 @default.
- W2152162065 creator A5075117420 @default.
- W2152162065 creator A5075157221 @default.
- W2152162065 creator A5076386757 @default.
- W2152162065 creator A5081642625 @default.
- W2152162065 creator A5086655742 @default.
- W2152162065 creator A5090255481 @default.
- W2152162065 creator A5090442302 @default.
- W2152162065 date "2015-09-01" @default.
- W2152162065 modified "2023-10-17" @default.
- W2152162065 title "Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry" @default.
- W2152162065 cites W1970648523 @default.
- W2152162065 cites W1973686119 @default.
- W2152162065 cites W1992915563 @default.
- W2152162065 cites W1995275377 @default.
- W2152162065 cites W2004380688 @default.
- W2152162065 cites W2007416864 @default.
- W2152162065 cites W2009720434 @default.
- W2152162065 cites W2010711123 @default.
- W2152162065 cites W2016487786 @default.
- W2152162065 cites W2021864751 @default.
- W2152162065 cites W2028578415 @default.
- W2152162065 cites W2031855605 @default.
- W2152162065 cites W2041598067 @default.
- W2152162065 cites W2042652801 @default.
- W2152162065 cites W2050231360 @default.
- W2152162065 cites W2052855201 @default.
- W2152162065 cites W2059698538 @default.
- W2152162065 cites W2061846271 @default.
- W2152162065 cites W2070152906 @default.
- W2152162065 cites W2071066672 @default.
- W2152162065 cites W2092503047 @default.
- W2152162065 cites W2096014841 @default.
- W2152162065 cites W2101648653 @default.
- W2152162065 cites W2111326065 @default.
- W2152162065 cites W2114031931 @default.
- W2152162065 cites W2119410505 @default.
- W2152162065 cites W2138498369 @default.
- W2152162065 cites W2139176812 @default.
- W2152162065 cites W2153202563 @default.
- W2152162065 cites W2154643481 @default.
- W2152162065 cites W2165207421 @default.
- W2152162065 cites W2222059886 @default.
- W2152162065 cites W2240465506 @default.
- W2152162065 cites W4293203547 @default.
- W2152162065 doi "https://doi.org/10.1016/s1470-2045(15)00169-2" @default.
- W2152162065 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26256760" @default.
- W2152162065 hasPublicationYear "2015" @default.
- W2152162065 type Work @default.
- W2152162065 sameAs 2152162065 @default.
- W2152162065 citedByCount "449" @default.
- W2152162065 countsByYear W21521620652015 @default.
- W2152162065 countsByYear W21521620652016 @default.
- W2152162065 countsByYear W21521620652017 @default.
- W2152162065 countsByYear W21521620652018 @default.
- W2152162065 countsByYear W21521620652019 @default.
- W2152162065 countsByYear W21521620652020 @default.
- W2152162065 countsByYear W21521620652021 @default.
- W2152162065 countsByYear W21521620652022 @default.
- W2152162065 countsByYear W21521620652023 @default.
- W2152162065 crossrefType "journal-article" @default.
- W2152162065 hasAuthorship W2152162065A5000874374 @default.
- W2152162065 hasAuthorship W2152162065A5002179064 @default.
- W2152162065 hasAuthorship W2152162065A5003947352 @default.
- W2152162065 hasAuthorship W2152162065A5004172458 @default.
- W2152162065 hasAuthorship W2152162065A5004552630 @default.
- W2152162065 hasAuthorship W2152162065A5012101254 @default.
- W2152162065 hasAuthorship W2152162065A5015242520 @default.
- W2152162065 hasAuthorship W2152162065A5021170936 @default.